Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

PSMA PET/CT may be new ‘gold standard’ for prostate cancer staging

Publish date:: July 21, 2020

Key clinical point: Prostate-specific membrane antigen (PSMA) PET/CT was 27% more accurate than conventional imaging for staging high-risk prostate cancer.

Major finding: The accuracy was 92% for PSMA PET/CT and 65% for CT and bone scintigraphy (P < .001) in detecting local and distant metastases.

Study details: A phase 3 trial of 302 men treated at 10 hospitals across Australia.

Disclosures: The study was funded by the Prostate Cancer Foundation of Australia. Dr. Hofman said he has no relevant conflicts of interest.

Citation:

Hofman M et al. Lancet. Mar 22, 2020. doi: 10.1016/S0140-6736(20)30314-7.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Genitourinary Cancer

Study shows no link between race and mortality in clear cell RCC,

Four factors may predict better survival with cabozantinib in mRCC,

Focal radiation boost nets better outcomes in prostate cancer,

Fear of recurrence highly prevalent in RCC survivors,

Immune checkpoint inhibitors don’t increase COVID-19 incidence or mortality, studies suggest,